



Attorney Docket No. CUTLER-08294

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Stefan Kwiatkowski *et al.*
Serial No.: 10/715,904
Filed: 11/18/03
Entitled: **Stereospecific Enrichment of Heterocyclic Enantiomers**

Group No.: 1625
Examiner: Seaman

**INFORMATION DISCLOSURE
STATEMENT TRANSMITTAL**

Assistant Commissioner for Patents
Washington, D.C. 20231

| | |
|---|-----------------------------|
| CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8(a)(1)(i)(A) | |
| I hereby certify that this correspondence (along with any referred to as being attached or enclosed) is, on the date shown below, being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231. | |
| Dated: <u>September 9, 2005</u> | By: <u>Kelly J. Collins</u> |

Sir or Madam:

Enclosed please find an Information Disclosure Statement and Form PTO-1449, including copies of the references contained thereon, for filing in the U.S. Patent and Trademark Office.

The Commissioner is hereby authorized to charge any additional fee or credit overpayment to our Deposit Account No. 08-1290. An originally executed duplicate of this transmittal is enclosed for this purpose.

Dated: September 9, 2005

Thomas W. Brown
Thomas W. Brown
Registration No. 50,002

MEDLEN & CARROLL, LLP
220 Montgomery Street, Suite 2200
San Francisco, California 94104
617/252-3353




IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Stefan Kwiatkowski *et al.*
Serial No.: 10/715,904
Filed: 11/18/03
Entitled: **Stereospecific Enrichment of Heterocyclic Enantiomers**

Group No.: 1625
Examiner: Seaman

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

| | |
|--|--|
| CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8(a)(1)(i)(A) | |
| I hereby certify that this correspondence (along with any referred to as being attached or enclosed) is, on the date shown below, being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 | |
| Dated: <u>September 9, 2005</u> | By: <u></u> Kelly J. Collins |

Sir or Madam:


The citations listed below, copies attached, may be material to the examination of the above-identified application, and are therefore submitted in compliance with the duty of disclosure defined in 37 C.F.R. §§ 1.56 and 1.97. The Examiner is requested to make these citations of official record in this application.

The following printed publications are referred to in the body of the specification:

- U.S. Patent No. 4,302,460 to Davies *et al.*;
 - U.S. Patent No. 5,079,264 to MacLean *et al.*;
 - U.S. Patent No. 5,011,931 to MacLean *et al.*;
 - WO 91/02724; and
 - Morita *et al.*, "Synthesis and Absolute Configuration of the Enantiomers of 7-Fluoro-1-methyl-3-(methylsulfinyl)-4(1*H*)-quinolinone (Flosequinan)," *Chem. Pharm. Bull.*, 42(10): 2157-2160 (1994).
- 09/14/2005 BABRAHA1 00000015 10715904
01 FC:1806
180.00 OP

This Information Disclosure Statement under 37 C.F.R. §§ 1.56 and 1.97 is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one or more of these citations constitutes prior art.

Dated: September 9, 2005



Thomas W. Brown
Registration No. 50,002

MEDLEN & CARROLL, LLP
101 Howard Street, Suite 305
San Francisco, California 94105
415/904-6500

FORM PTO-1449
(Modified)U.S. Department of Commerce
Patent and Trademark Office

Attorney Docket No.: CUTLER-08294

Serial No.: 10/715,904

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Use Several Sheets If Necessary)

(37 CFR § 1.98(b))

Applicant: Stefan Kwiatkowski *et al.*

Filing Date: 11/18/03

Group Art Unit: 1625

U.S. PATENT DOCUMENTS

| Examiner Initials | Cite No. | Serial / Patent Number | Issue Date | Applicant / Patentee | Class | Subclass | Filing Date |
|-------------------|----------|------------------------|------------|-----------------------|-------|----------|-------------|
| | 1 | 4,302,460 | 11/24/81 | Davies <i>et al.</i> | 424 | 258 | 03/24/80 |
| | 2 | 5,011,931 | 04/30/91 | MacLean <i>et al.</i> | 546 | 155 | 11/07/88 |
| | 3 | 5,079,264 | 01/07/92 | MacLean <i>et al.</i> | 514 | 629 | 03/01/91 |
| | 4 | | | | | | |
| | 5 | | | | | | |
| | 6 | | | | | | |
| | 7 | | | | | | |

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

| Document Number | Publication Date | Country / Patent Office | Class | Subclass | Translation Yes |
|-----------------|------------------|-------------------------|-------|----------|--------------------|
| 8 | WO 91/02724 | 07.03.91 | PCT | | X |
| 9 | | | | | |
| 10 | | | | | |
| 11 | | | | | |
| 12 | | | | | |
| 13 | | | | | |
| 14 | | | | | |

OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

| | |
|----|---|
| 15 | Morita <i>et al.</i> , "Synthesis and Absolute Configuration of the Enantiomers of 7-Fluoro-1-methyl-3-(methylsulfinyl)-4(1 <i>H</i>)-quinolinone (Flosequinan)," <i>Chem. Pharm. Bull.</i> , 42(10): 2157-2160 (1994) |
| 16 | |
| 17 | |
| 18 | |
| 19 | |

Examiner:

Date Considered:

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.